GTC Biotherapeutics (fka GTCB)

[floblu14]

>There should be enough information uncovered by the P2 clinicals to get a very solid idea of the efficacy of Atryn.<

Although GTC has had only one new patent application since March, this last one in August needs careful analysis -

Is GTC on to something that will increase survival in DIC patients?

>Recombinant human AT (ATryn(R); GTC Biotherapeutics, Framingham, MA) was used in this experiment<

>The methods and compositions provided can be used, for example, for the treatment or prophylaxis of sepsis, disseminated intravascular coagulation (DIC), peritonitis, ovarian cancer, or for any gastrointestinal injury or infection.<

>....intraabdominal administration of a high dose of rhAT by peritoneal lavage reduced intraabdominal coagulation activation and fibrin formation, without severe derangements in coagulation that could lead to serious bleeding complications, and concomitantly improved i bacterial clearance and inflammatory responses. This resulted in reduced inflammation and coagulation activation in the pulmonary compartment, and ultimately in survival.<

Anyone have the time to decipher this further? TIA

http://v3.espacenet.com/publicationDetails/description?CC=WO&NR=2008100258A1&KC=A1&FT=D&date=20080821&DB=EPODOC&locale=en_V3